206 related articles for article (PubMed ID: 35836132)
1. A comprehensive prognostic and immune analysis of enhancer RNA identifies IGFBP7-AS1 as a novel prognostic biomarker in Uterine Corpus Endometrial Carcinoma.
Liu J; Yin J; Wang Y; Cai L; Geng R; Du M; Zhong Z; Ni S; Huang X; Yu H; Bai J
Biol Proced Online; 2022 Jul; 24(1):9. PubMed ID: 35836132
[TBL] [Abstract][Full Text] [Related]
2. TBX5-AS1, an enhancer RNA, is a potential novel prognostic biomarker for lung adenocarcinoma.
Cheng L; Han T; Chen B; Nie K; Peng W
BMC Cancer; 2021 Jul; 21(1):794. PubMed ID: 34238250
[TBL] [Abstract][Full Text] [Related]
3. Pan-Cancer Gene Analysis of m6A Modification and Immune Infiltration in Uterine Corpus Endometrial Carcinoma.
Xie BF; Xia Y; Lin DH; Lian B; Zhang ML; Liu L; Qin CR
Comput Intell Neurosci; 2022; 2022():6530884. PubMed ID: 36199963
[TBL] [Abstract][Full Text] [Related]
4. SPRY4-AS1, A Novel Enhancer RNA, Is a Potential Novel Prognostic Biomarker and Therapeutic Target for Hepatocellular Carcinoma.
Ye M; Wang S; Qie JB; Sun PL
Front Oncol; 2021; 11():765484. PubMed ID: 34671565
[TBL] [Abstract][Full Text] [Related]
5. Identification of Five m6A-Related lncRNA Genes as Prognostic Markers for Endometrial Cancer Based on TCGA Database.
Shan L; Lu Y; Xiang CC; Zhu X; Zuo ED; Cheng X
J Immunol Res; 2022; 2022():2547029. PubMed ID: 35571565
[TBL] [Abstract][Full Text] [Related]
6. m6A-related long noncoding RNAs predict prognosis and indicate therapeutic response in endometrial carcinoma.
Zhou X; Zhang H; Duan Y; Zhu J; Dai H
J Clin Lab Anal; 2023 Jan; 37(1):e24813. PubMed ID: 36525280
[TBL] [Abstract][Full Text] [Related]
7. Identification and validation of oxeiptosis-associated lncRNAs and prognosis-related signature genes to predict the immune status in uterine corpus endometrial carcinoma.
Niu L; Wu Z
Aging (Albany NY); 2023 May; 15(10):4236-4252. PubMed ID: 37211398
[TBL] [Abstract][Full Text] [Related]
8. An Integrative Analysis Revealing ZFHX4-AS1 as a Novel Prognostic Biomarker Correlated with Immune Infiltrates in Ovarian Cancer.
Huang C; Cui H; Lang X; Zhao F
J Immunol Res; 2022; 2022():9912732. PubMed ID: 35795530
[TBL] [Abstract][Full Text] [Related]
9. Identification of Hub Genes Correlated With Poor Prognosis for Patients With Uterine Corpus Endometrial Carcinoma by Integrated Bioinformatics Analysis and Experimental Validation.
Yuan Y; Chen Z; Cai X; He S; Li D; Zhao W
Front Oncol; 2021; 11():766947. PubMed ID: 34868993
[TBL] [Abstract][Full Text] [Related]
10. Identification of Enhancer RNA CDK6-AS1 as a Potential Novel Prognostic Biomarker in Gastric Cancer.
Yang S; Zou X; Yang H; Li J; Zhang A; Zhang L; Li C; Zhu L; Ma Z
Front Genet; 2022; 13():854211. PubMed ID: 35571043
[No Abstract] [Full Text] [Related]
11. KDM4B, a potential prognostic biomarker revealed by large-scale public databases and clinical samples in uterine corpus endometrial carcinoma.
Zhang M; Liu Y; Hou S; Wang Y; Wang C; Yin Y; Chen X
Mol Omics; 2022 Jul; 18(6):506-519. PubMed ID: 35485290
[TBL] [Abstract][Full Text] [Related]
12. Construction of dysregulated long non-coding RNA-associated competing endogenous RNA network in uterine corpus endometrial carcinoma.
Li N; Mi P; Hu Y
Transl Cancer Res; 2020 Feb; 9(2):669-682. PubMed ID: 35117412
[TBL] [Abstract][Full Text] [Related]
13. Identification and Validation of Cuproptosis-Related Prognostic Signature and Associated Regulatory Axis in Uterine Corpus Endometrial Carcinoma.
Chen Y
Front Genet; 2022; 13():912037. PubMed ID: 35937995
[No Abstract] [Full Text] [Related]
14. Screening and validation of potential markers associated with uterine corpus endometrial carcinoma and polycystic ovary syndrome based on bioinformatics methods.
Wu R; Wu C; Zhu B; Li J; Zhao W
Front Mol Biosci; 2023; 10():1192313. PubMed ID: 37363398
[No Abstract] [Full Text] [Related]
15. Identification of an immune gene signature for predicting the prognosis of patients with uterine corpus endometrial carcinoma.
Zhou C; Li C; Yan F; Zheng Y
Cancer Cell Int; 2020 Nov; 20(1):541. PubMed ID: 33292199
[TBL] [Abstract][Full Text] [Related]
16. Development of an Oxidative Phosphorylation-Related and Immune Microenvironment Prognostic Signature in Uterine Corpus Endometrial Carcinoma.
Liu J; Chen T; Yang M; Zhong Z; Ni S; Yang S; Shao F; Cai L; Bai J; Yu H
Front Cell Dev Biol; 2021; 9():753004. PubMed ID: 34901000
[No Abstract] [Full Text] [Related]
17. Identification of an Immune-Related LncRNA Prognostic Signature in Uterine Corpus Endometrial Carcinoma Patients.
Sun XX; Wen HQ; Zhan BX; Yang P
Clin Lab; 2021 Nov; 67(11):. PubMed ID: 34758230
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive Analysis of Enhancer RNAs Identifies LINC00689 and ELFN1-AS1 as Novel Prognostic Biomarkers in Uveal Melanoma.
Zhao S; Jiang H; Liu J; Li DY; Li B; Long QR; Zheng L; Gu H
Dis Markers; 2022; 2022():5994800. PubMed ID: 35251374
[TBL] [Abstract][Full Text] [Related]
19. LINC02257, an Enhancer RNA of Prognostic Value in Colon Adenocarcinoma, Correlates With Multi-Omics Immunotherapy-Related Analysis in 33 Cancers.
Xiao J; Liu Y; Yi J; Liu X
Front Mol Biosci; 2021; 8():646786. PubMed ID: 33996902
[TBL] [Abstract][Full Text] [Related]
20. [Dysregulation of MAD2L1/CAMK2A/PTTG1 Gene Cluster Maintains the Stemness Characteristics of Uterine Corpus Endometrial Carcinoma].
Zheng J; Zhang YW; Pan ZF
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2021 Oct; 43(5):685-695. PubMed ID: 34728029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
